Harmony Biosciences Holdings (HRMY) Cash from Operations (2019 - 2026)
Harmony Biosciences Holdings (HRMY) posted Cash from Operations of 27760000.0 for Q1 2026, down 77.99% sequentially from 126151000.0 in Q4 2025, and down 18.32% YoY from 33987000.0 in Q1 2025.
Harmony Biosciences Holdings (HRMY) Cash from Operations (2019 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported Cash from Operations for 8 years, with the latest figure at 27760000.0 in Q1 2026.
- Quarterly Cash from Operations fell 18.32% year-over-year to 27760000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 341972000.0 (up 53.58% YoY) and the FY2025 annual result came in at 348199000.0, up 58.4% from the prior year.
- Cash from Operations declined to 27760000.0 in Q1 2026 per HRMY's latest filing, from 126151000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 126151000.0 in Q4 2025 and troughed at 26678000.0 in Q4 2022.
- A 5-year average of 56449000.0 and a median of 42617000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations slipped 28.92% in 2022, then surged 187.37% in 2023.
- Over 5 years, Cash from Operations stood at 26678000.0 in 2022, then soared by 187.37% to 76665000.0 in 2023, then decreased by 1.44% to 75562000.0 in 2024, then jumped by 66.95% to 126151000.0 in 2025, then slumped by 77.99% to 27760000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 27760000.0, 126151000.0, and 108734000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 92.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 92.43 Mn |
| Jun 30, 2026 | 92.43 Mn |
| Mar 31, 2026 | 27.76 Mn |
| Mar 31, 2026 | 27.76 Mn |
| Dec 31, 2025 | 126.15 Mn |
| Dec 31, 2025 | 126.15 Mn |
| Sep 30, 2025 | 108.73 Mn |
| Sep 30, 2025 | 108.73 Mn |
| Jun 30, 2025 | 79.33 Mn |
| Jun 30, 2025 | 79.33 Mn |
| Mar 31, 2025 | 33.99 Mn |
| Mar 31, 2025 | 33.99 Mn |
| Dec 31, 2024 | 75.56 Mn |
| Dec 31, 2024 | 75.56 Mn |
| Sep 30, 2024 | 70.50 Mn |
| Sep 30, 2024 | 70.50 Mn |
| Jun 30, 2024 | 42.62 Mn |
| Jun 30, 2024 | 42.62 Mn |
| Mar 31, 2024 | 31.14 Mn |
| Mar 31, 2024 | 31.14 Mn |